Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ALXN

Alexion Pharmaceuticals (ALXN) Stock Price, News & Analysis

Alexion Pharmaceuticals logo

About Alexion Pharmaceuticals Stock (NASDAQ:ALXN)

Advanced Chart

Key Stats

Today's Range
$182.50
$182.50
50-Day Range
$179.45
$186.61
52-Week Range
$99.91
$187.45
Volume
10 shs
Average Volume
3.31 million shs
Market Capitalization
$40.34 billion
P/E Ratio
59.64
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alexion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALXN Stock News Headlines

Alexion Stock Price History
Is This Stock the 'Next Nvidia'?
'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, and has now reached every AI company in America... including Nvidia, Microsoft, and Meta.tc pixel
Alexion’s ravulizumab granted FDA orphan designation
Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months
AstraZeneca's Alexion Inks Deal With Pan-Canadian Pharmaceutical Alliance
See More Headlines

ALXN Stock Analysis - Frequently Asked Questions

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its earnings results on Thursday, April, 29th. The biopharmaceutical company reported $3.52 EPS for the quarter, topping analysts' consensus estimates of $3.16 by $0.36. The business's revenue for the quarter was up 13.3% on a year-over-year basis.

Alexion Pharmaceuticals subsidiaries include Portola Pharmaceuticals Inc., Achillion Pharmaceuticals, Syntimmune, Wilson Therapeutics, Synageva BioPharma Corp., Enobia Pharma Corp., Taligen Therapeutics Inc., and others.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alexion Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Bristol Myers Squibb (BMY), Tesla (TSLA), Netflix (NFLX), Gilead Sciences (GILD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
4/29/2021
Today
8/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALXN
CIK
899866
Fax
N/A
Employees
3,837
Year Founded
1992

Profitability

EPS (Trailing Twelve Months)
$11.60
Trailing P/E Ratio
59.64
Forward P/E Ratio
13.95
P/E Growth
0.93
Net Income
$603.40 million
Net Margins
10.89%
Pretax Margin
N/A
Return on Equity
23.43%
Return on Assets
15.06%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
4.52
Quick Ratio
3.96

Sales & Book Value

Annual Sales
$6.07 billion
Price / Sales
6.65
Cash Flow
$22.81 per share
Price / Cash Flow
8.00
Book Value
$53.24 per share
Price / Book
3.43

Miscellaneous

Outstanding Shares
221,019,000
Free Float
N/A
Market Cap
$40.34 billion
Optionable
Optionable
Beta
1.25

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ALXN) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners